Dr Hanneke W M van Laarhoven Medische Oncologie
- Slides: 6
Dr. Hanneke W. M. van Laarhoven Medische Oncologie Academisch Medische Centrum Blik op de toekomst: lopende en geplande DOCG studies • Neoadjuvante chemoradiatie: surgery when needed (pre. SANO) • Neoadjuvante chemoradiatie: targeted treatment (TRAP) • Neoadjuvante/definitieve chemoradiatie: surgery if possible (TOR) • Definitieve chemoradiatie: dosisintensificatie (ART-DECO) • Dataregistratie (POCOP)
pre. SANO pre- Surgery As Needed for Oesophageal carcinoma A single-arm feasibility trial Primary endpoint • Correlation between the clinical response during CRE-I and CRE-II and the final pathological response in the resection specimen Secondary endpoints • Serious complications during endoscopic and endosonographic tissue sampling • R 0 -resection rates for all included patients that undergo resection
TRAP Chemoradiation, TRAstuzumab and Pertuzumab in resectable HER 2+ esophageal carcinoma A single arm feasibility study Primary endpoint • Withdrawal rate from surgery Secondary endpoints • p. CR • Toxicity • Post-operative complications
TOR Chemoradiotherapy followed by resection for patients with gevolgd a T 4 b oesofagus carcinoma Primary endpoint • R 0 resection (≥ 80% ) Secondary endpoints • Post-operative complications • Mortality • Quality of life
ART-DECO A Randomized Trial of Dose Escalation in definitive Chemoradiotherapy for patients with Oesophageal cancer Landelijk Platform Radiotherapie voor Gastro Enterologische tumoren Primary endpoint • Local recurrence rate (≥ 15% difference) Secondary endpoints • Grade 3 -4 toxicity • Survival
POCOP Prospective Observational Cohort Study of Oesophageal-gastric cancer Patients Acknowledgments • Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (pre. SANO) • Maarten Anderegg, Mark van Berge Henegouwen (TOR) • Maarten Hulshof (ART-DECO) • Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)